Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | MicrobiomeTrials← Back to trialsNCT07284901
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-01-12Est. Completion: 2028-03-27
Enrollment target: 1,700 participants Locations- Kailera Clinical Site, Cullman, Alabama, United States
- Kailera Clinical Site, Phoenix, Arizona, United States
- Kailera Clinical Site, Sun City, Arizona, United States
- Kailera Clinical Site, Little Rock, Arkansas, United States
- Kailera Clinical Site, Escondido, California, United States
- Kailera Clinical Site, Northridge, California, United States
- Kailera Clinical Site, Oceanside, California, United States
- Kailera Clinical Site, Toluca Lake, California, United States
- Kailera Clinical Site, Stamford, Connecticut, United States
- Kailera Clinical Site, Jupiter, Florida, United States
- Kailera Clinical Site, Orange City, Florida, United States
- Kailera Clinical Site, Lilburn, Georgia, United States
- Kailera Clinical Site, Skokie, Illinois, United States
- Kailera Clinical Site, Springfield, Illinois, United States
- Kailera Clinical Site, Newton, Kansas, United States
- Kailera Clinical Site, Shreveport, Louisiana, United States
- Kailera Clinical Site, Columbia, Maryland, United States
Other microbiome trials you might be interested in
Insulin ResistanceObesity
Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist f…
Bethesda, United StatesEst. completion Mar 1, 2030
ExercisePhysical ActivityGamificationUniversity StudentCollege Student
The increasing incidence of cardiovascular disease (CVD) and related mortality is now recognized as a global emergency. …
Bursa, Turkey (Türkiye)Completed Mar 20, 2026
Kailera Clinical Site, Farmington Hills, Michigan, United StatesKailera Clinical Site, Missoula, Montana, United StatesKailera Clinical Site, Lincoln, Nebraska, United StatesKailera Clinical Site, Las Vegas, Nevada, United StatesKailera Clinical Site, Albany, New York, United StatesKailera Clinical Site, Laurelton, New York, United StatesKailera Clinical Site, Greensboro, North Carolina, United StatesKailera Clinical Site, Morehead City, North Carolina, United StatesKailera Clinical Site, Chickasha, Oklahoma, United StatesKailera Clinical Site, Spartanburg, South Carolina, United StatesKailera Clinical Site, Chattanooga, Tennessee, United StatesKailera Clinical Site, Amarillo, Texas, United StatesKailera Clinical Site, Brownsville, Texas, United StatesKailera Clinical Site, DeSoto, Texas, United StatesKailera Clinical Site, Tomball, Texas, United StatesKailera Clinical Site, Salt Lake City, Utah, United StatesKailera Clinical Site, Richmond, Virginia, United StatesKailera Clinical Site, Bruce, Australian Capital Territory, AustraliaKailera Clinical Site, Blacktown, New South Wales, AustraliaKailera Clinical Site, Kanwal, New South Wales, AustraliaKailera Clinical Site, Leichhardt, New South Wales, AustraliaKailera Clinical Site, Sydney, New South Wales, AustraliaKailera Clinical Site, Sydney, New South Wales, AustraliaKailera Clinical Site, Wollongong, New South Wales, AustraliaKailera Clinical Site, Herston, Queensland, AustraliaKailera Clinical Site, Camberwell, Victoria, AustraliaKailera Clinical Site, Melbourne, Victoria, AustraliaKailera Clinical Site, Grafton, Auckland, New ZealandKailera Clinical Site, New Lynn, Auckland, New ZealandKailera Clinical Site, Silverdale, Auckland, New ZealandKailera Clinical Site, Takapuna, Auckland, New ZealandKailera Clinical Site, Nawton, Hamilton, New ZealandKailera Clinical Site, Auckland, New ZealandKailera Clinical Site, Hastings, New ZealandKailera Clinical Site, Nelson, New ZealandObesity Type 2 Diabetes MellitusObesity & Overweight
This study will examine how eating behaviour changes during the first 18 months of treatment with obesity medications in…
Dublin, IrelandEst. completion Aug 25, 2026